The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of STAT3 polymorphisms to predict overall survival in patients treated with interferon-alpha for metastatic renal cell carcinoma.
Masatoshi Eto
No relevant relationships to disclose
Tomomi Kamba
No relevant relationships to disclose
Hideaki Miyake
No relevant relationships to disclose
Masato Fujisawa
No relevant relationships to disclose
Takao Kamai
No relevant relationships to disclose
Hirotsugu Uemura
No relevant relationships to disclose
Taiji Tsukamoto
No relevant relationships to disclose
Haruhito Azuma
No relevant relationships to disclose
Akio Matsubara
No relevant relationships to disclose
Kazuo Nishimura
No relevant relationships to disclose
Tsuyoshi Nakamura
No relevant relationships to disclose
Osamu Ogawa
No relevant relationships to disclose
Seiji Naito
No relevant relationships to disclose